Rigel Pharmaceuticals, Inc. (RIGL)
45.11
-0.78
(-1.70%)
USD |
NASDAQ |
Aug 24, 16:00
45.16
+0.06
(+0.12%)
After-Hours: 20:00
Rigel Pharmaceuticals Enterprise Value : 786.10M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 786.10M |
| August 21, 2026 | 800.65M |
| August 20, 2026 | 788.71M |
| August 19, 2026 | 820.61M |
| August 18, 2026 | 758.30M |
| August 17, 2026 | 736.48M |
| August 14, 2026 | 738.90M |
| August 13, 2026 | 705.51M |
| August 12, 2026 | 725.66M |
| August 11, 2026 | 728.46M |
| August 10, 2026 | 721.74M |
| August 07, 2026 | 693.95M |
| August 06, 2026 | 676.23M |
| August 05, 2026 | 699.73M |
| August 04, 2026 | 666.53M |
| August 03, 2026 | 642.84M |
| July 31, 2026 | 631.27M |
| July 30, 2026 | 654.59M |
| July 29, 2026 | 673.43M |
| July 28, 2026 | 662.80M |
| July 27, 2026 | 642.09M |
| July 24, 2026 | 629.97M |
| July 23, 2026 | 631.46M |
| July 22, 2026 | 649.74M |
| July 21, 2026 | 677.91M |
| Date | Value |
|---|---|
| July 20, 2026 | 684.62M |
| July 17, 2026 | 700.85M |
| July 16, 2026 | 721.93M |
| July 15, 2026 | 712.79M |
| July 14, 2026 | 712.60M |
| July 13, 2026 | 715.03M |
| July 10, 2026 | 738.34M |
| July 09, 2026 | 760.92M |
| July 08, 2026 | 745.43M |
| July 07, 2026 | 738.53M |
| July 06, 2026 | 695.53M |
| July 02, 2026 | 666.90M |
| July 01, 2026 | 658.88M |
| June 30, 2026 | 674.36M |
| June 29, 2026 | 620.56M |
| June 26, 2026 | 614.09M |
| June 25, 2026 | 582.67M |
| June 24, 2026 | 574.54M |
| June 23, 2026 | 557.17M |
| June 22, 2026 | 559.38M |
| June 18, 2026 | 507.27M |
| June 17, 2026 | 515.77M |
| June 16, 2026 | 498.95M |
| June 15, 2026 | 516.69M |
| June 12, 2026 | 506.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 1.000B |
| Cytokinetics, Inc. | 10.80B |
| Perspective Therapeutics, Inc. | 131.02M |
| Capricor Therapeutics, Inc. | 248.25M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 17.29M |
| Revenue (Quarterly) | 78.70M |
| Total Expenses (Quarterly) | 61.41M |
| EPS Diluted (Quarterly) | 0.8835 |
| Gross Profit Margin (Quarterly) | 89.17% |
| Profit Margin (Quarterly) | 21.97% |
| Earnings Yield | 36.18% |
| Operating Earnings Yield | 9.87% |
| Normalized Earnings Yield | 36.20 |